Krentz Andrew J, Clough Geraldine, Byrne Christopher D
Department of Diabetes and Endocrinology, Southampton General Hospital, Southampton SO16 6YD, UK.
Diabetes Obes Metab. 2007 Nov;9(6):781-91. doi: 10.1111/j.1463-1326.2007.00670.x.
Convention partitions the complications of diabetes into two main subtypes. First are the diabetes-specific microvascular complications of retinopathy, nephropathy and neuropathy; second are the atherothrombotic macrovascular complications that account for the majority of premature deaths. Pathological interactions between microvascular and macrovascular complications, for example, nephropathy and macrovascular disease, are common. Similar mechanisms and shared risk factors drive the development and progression of both small and large vessel disease. This concept has therapeutic implications. Mounting evidence points to the need for multifactorial strategies to prevent vascular complications in subjects with diabetes and/or the metabolic syndrome. We advocate a combined therapeutic approach that addresses small and large vessel disease. Preferential use should be made of drug regimens that (i) maximize vascular protection, (ii) reduce the risk of iatrogenic vascular damage and (iii) minimize the increasing problem of polypharmacy.
传统上将糖尿病并发症分为两种主要亚型。首先是糖尿病特有的微血管并发症,包括视网膜病变、肾病和神经病变;其次是动脉粥样硬化性大血管并发症,这是导致大多数过早死亡的原因。微血管和大血管并发症之间的病理相互作用很常见,例如肾病和大血管疾病。相似的机制和共同的危险因素推动了小血管和大血管疾病的发生和发展。这一概念具有治疗意义。越来越多的证据表明,需要采取多因素策略来预防糖尿病和/或代谢综合征患者的血管并发症。我们提倡一种综合治疗方法,同时解决小血管和大血管疾病问题。应优先使用能(i)最大限度地提供血管保护、(ii)降低医源性血管损伤风险以及(iii)将日益严重的多重用药问题降至最低的药物治疗方案。